Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: memo to Investors: what goes UP will come DOWN

August 23, 2018 5:16pm

Today’s trend is an admission that the sector lacks pricing sustainability which suppresses a value indicator …

Pre-open indication: 4 HITs and 4 MISS (news and strength were sold into)

Algorithms might account for identifying patterns and/or anomalies in sector and market performance; but cannot issue explanations for missing, confusing and often contradictory data!

No hard sell, get on the list for a 30 day trial!

Henry’omics:

Sector stocks fell on Thursday as markets fretted over President Trump legal troubles dampening investor sentiment.

As far as “our” universe was concerned – traders were reaping profits from a five (5) session upside “run”!

In talking, many wanted to exit now and be ready – early for the month’s end and upcoming holiday.

From the pre-open newsletter: “What light through yonder window breaks? I ask having thought we would have a continued upside trend, “don't swear by the moon” the sector replied.”

I also stated, “There is going to be a sector sell-off based on trading seeking to capitalize on many of the ‘ups’…”

Of the 45 companies covered on Thursday; 26 downside equities finished in a range of -0.13% (XON) to -7.48% (RARE) while the 16 upside equities oscillated from +0.13% (ONCE) to +6.13% (BLFS) with 3 flat close (ONVO, BSTG and RENE.L).

Daily analytics and metrics:

The Dow closed down -76.69 points or -0.3% to 25,656.91
The S&P closed down -4.84 points or -0.17% to 2,856.98
The NASDAQ closed down -10.64 points or -0.13% to 7,878.46

Pre-open indications: 4 hits and 4 miss

Applied Genetic Technologies (AGTC) closed down -$0.05 – hit;
BioLife Solutions (BLFS) closed up +$1.44 – miss;
bluebird bio (BLUE) closed down -$1.05 – miss;
CRISPR Therapeutics (CRSP) closed down -$0.32 – miss;
Global Blood Technologies (GBT) closed down -$1.70 – miss;
uniQure (QURE) closed up +$0.19 – hit;
Editas Medicine (EDIT) closed down -$0.83 – hit;
Intellia Therapeutics (NTLA) closed down -$0.16 – hit;
Verastem Oncology (VSTM) closed up +$0.28 – miss;

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 20/18 and 5 flats;
The second hour slipped negative with an A/DL of 12/31 and 2 flats;
The mid-day was negative with an A/DL of 16/25 and 3 flats;
The close was negative with an A/DL of 16/26 and 3 flat;

The five (5) largest trend lines:

… The greatest volume to the downside: SGMO, IONS, BMRN, ALNY, GBT and XON

… Upside volume was weighted to: VSTM, MDXG, BLFS, AXGN and VCEL

… Leadership ($) to the downside: RARE (-$6.11), BMRN (-$2.44), GBT (-$1.70), IONS (-$1.47) and BLUE (-$1.05)

… Best moves ($) to the upside: AXGN (+$1.55), BLFS (+$1.44), SAGE (+$0.96), FIXX (+$0.79) and BOLD (+$0.55)

The iShares NASDAQ Biotechnology (IBB) closed:

Thursday was down -0.58%
Wednesday was up +0.71%
Tuesday was up +0.93%
Monday was down -0.17%
Friday was up +0.02%
Last Thursday was up +0.77%

August sessions:

Thursday closed NEGATIVE with 26 decliners, 16 advancers and 3 flat;

Wednesday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Tuesday closed POSITIVE with 9 decliners, 36 advancers and 0 flat;

Monday closed POSITIVE with 16 decliners, 23 advancers and 6 flat;

Friday closed POSITIVE with 18 decliners, 24 advancers and 3 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Wednesday closed NEGATIVE with 36 decliners, 6 advancers and 3 flat;

Tuesday closed POSITIVE with 13 decliners, 28 advancers and 4 flat;

Monday closed NEGATIVE with 24 decliners, 19 advancers and 2 flat;

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Wednesday closed NEGATIVE with 25 decliners, 16 advancers and 4 flat;

Tuesday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Monday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Friday closed NEGATIVE with 37 decliners, 4 advancers and 4 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Last Wednesday (8/1) closed NEGATIVE with 23 decliners, 21 advancers and 1 flat;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.